Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents
  • CME
  • CE

Adam M. Brufsky, MD, PhD
Released: April 13, 2020

Final Thoughts on Clinical Practice Implications

Implications for Practice

To summarize, I consider HER2 TKIs to be a very reasonable choice for treating patients with HER2-positive MBC in the third-line setting and beyond. The neratinib data are interesting and the tucatinib data are particularly strong. The ADC, trastuzumab deruxtecan, is a major new therapy in the third-line setting, and I suspect it will likely move to earlier settings. These earlier settings could include the postneoadjuvant setting where T-DM1 is now the standard of care; the second-line therapy for residual disease (DESTINY-Breast03); and treatment for HER2-low disease (DESTINY-Breast04). The benefit of margetuximab is unclear, but it may be of use in patients who are CD16A-158F carriers.

Clinical Pearls for Nurses and Pharmacists

Nurses and pharmacists play key roles in the multidisciplinary team caring for patients with HER2-positive MBC, particularly regarding managing and counseling patients on toxicities. Of the therapies we discussed here, there are 2 with important AEs of interest: the pan-HER TKI neratinib, which is associated with diarrhea; and T-DXd, which is associated with ILD.

The diarrhea associated with neratinib can be quite severe and lead to treatment discontinuations.[23] However, it is manageable with dose escalation of neratinib and prophylactic antidiarrheals (ie, loperamide with or without budesonide or colestipol); these preventive strategies markedly reduced the incidence of high-grade diarrhea in patients receiving neratinib.[17,24,25]

The ILD associated with T-DXd can be fatal, which is why it is important to counsel patients on prompt reporting of respiratory symptoms (eg, cough, dyspnea).[15] However, we have effective toxicity management algorithms in place that rely on monitoring, starting steroids immediately upon suspicion of ILD, and, depending on grade, either holding treatment, modifying the dose, or discontinuing treatment.

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Daiichi Sankyo, Inc.
Puma Biotechnology, Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?